'DEA Wants Nearly 1 Million Grams Of Delta-9 THC Manufactured For Research Next Year In Latest Schedule I Quota Hike' - MarijuanaMoment
Portfolio Pulse from Benzinga Newsdesk
The Drug Enforcement Administration (DEA) plans to significantly increase domestic production of delta-9 THC and other cannabinoids for research purposes in 2024. The agency also plans to maintain high levels of psychedelics production. The DEA has proposed nearly doubling the amount of psilocybin, psilocyn, and delta-9 THC manufactured compared to initial levels set for this year, while quintupling the production of ibogaine. The DEA's move comes amid a transition away from cannabinoid imports to domestic manufacturing.

November 02, 2023 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Increased domestic production of cannabinoids for research purposes by the DEA could potentially impact Aurora Cannabis Inc. (ACB) positively, as it may open up new opportunities for research collaborations and partnerships.
The DEA's move to increase domestic production of cannabinoids for research purposes could potentially create new opportunities for companies like Aurora Cannabis Inc. (ACB) that are involved in the production and distribution of cannabis and related products. This could lead to potential research collaborations and partnerships, which could positively impact the company's stock in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Canopy Growth Corporation (CGC) could potentially benefit from the DEA's plan to increase domestic production of cannabinoids for research purposes, as it may lead to new research collaborations and partnerships.
The DEA's move to increase domestic production of cannabinoids for research purposes could potentially create new opportunities for companies like Canopy Growth Corporation (CGC) that are involved in the production and distribution of cannabis and related products. This could lead to potential research collaborations and partnerships, which could positively impact the company's stock in the short term.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50